CDK2 and prostate carcinoma: Niu et al. (2015) suggested that miR-3619-5p inhibited lung cancer progression by modulating β-catenin 3′UTR. Zhang et al. (2018) indicated that miR-3619-5p repressed cell metastasis by inhibiting beta-catenin, cyclin-dependent kinase 2 (CDK2) and activating p21 in bladder carcinoma. In addition, CDKN1A-mediated miR-3619-5p was also reported to repress cell proliferation and promote cell apoptosis in prostate cancer (Li et al., 2017).